Attitudes of undergraduate university women towards HPV vaccination: a cross-sectional study in Ottawa, Canada
Tóm tắt
Persistent infection with certain subtypes of human papillomavirus (HPV) is a necessary cause of cervical cancer. Although two prophylactic vaccines have been licensed in Canada against cancerous subtypes of HPV, vaccine uptake has been lower than anticipated. The primary objective of this study was to determine the acceptability of catch-up HPV vaccination to undergraduate university women under the age of 25, by assessing their perceptions of HPV vaccination. A total of 401 University of Ottawa female undergraduate students participated in a cross-sectional bilingual web-based survey on HPV vaccination. The prevalence of immunization with at least 1 HPV vaccine dose was 49% in the study population. Although the overall attitude of study participants towards the vaccine was positive, vaccinated respondents had a more favourable attitude towards the vaccine than non-vaccinated respondents. Approximately half of the non-vaccinated respondents were interested in receiving the vaccine at some point in the future. The primary barriers to HPV vaccination identified by non-vaccinated respondents were lack of knowledge about the vaccines, potential vaccine side effects and cost of vaccination. Multivariable analysis comparing non-vaccinated respondents who intended to be vaccinated and those who did not suggests that the former group had a more favourable attitude towards the vaccine and would be influenced by doctor recommendation. Offering HPV vaccination for women aged 18 to 25 provides an opportunity to address suboptimal vaccination coverage in the population and may reduce health inequities demonstrated by variations in cervical cancer incidence within jurisdictions.
Tài liệu tham khảo
Watts LA, Joseph N, Wallace M, et al. HPV vaccine: a comparison of attitudes and behavioural perspectives between Latino and non-Latino women. Gynecol Oncol. 2009;112:577–82.
World Health Organization, WHO Guidance Note: Comprehensive cervical cancer prevention and control: a healthier future for girls and women. http://www.who.int/immunization/hpv/learn/comprehensive_cervical_cancer_who_2013.pdf (2013). Accessed 2 January 2016.
D'Andrilli G, Bovicelli A, Giordano A. HPV vaccines: state of the art. J Cell Physiol. 2010;224:601–4.
Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24(Supplement 1(0)):S4–S15.
Koutsky LA, Gallowat D, Holmes K. Epidemiology of genital human papillomavirus infection. Epidemiol Rev. 1988;10:122–63.
SOGC. Incidence and Prevalence of HPV in Canada. http://hpvinfo.ca/what-is-hpv/ (2007). Accessed 10 Jan 2016.
Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008;26(Suppl 10):K1–K16.
Merck & Co., Inc. Gardasil 9. https://www.gardasil9.com/ (2017). Accessed 15 Feb 2018.
PHAC. Update on the recommended Human Papillomavirus (HPV) vaccine immunization schedule. 2015. https://www.canada.ca/en/public-health/services/publications/healthy-living/update-recommended-human-papillomavirus-vaccine-immunization-schedule.html. Accessed 30 July 2018.
Medeiros LR, Rosa DD, da Rosa MI, et al. Efficacy of human papillomavirus vaccines: a systematic quantitative review. Int J Gynecol Cancer. 2009;19:1166–76.
Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:F2032.
PHAC-NACI. Update on Human Papillomavirus (HPV) Vaccines. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/12vol38/acs-dcc-1/index-eng.php#a5 (2012). Accessed 26 Nov 2015.
Toft L, Tolstrup M, Müller M, et al. Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults. Hum Vacc Immunother. 2014;10:1147–54.
PHAC. Recommendations on a Human Papillomavirus Immunization Program. 2007. http://publications.gc.ca/collections/collection_2008/phac-aspc/HP40-29-2008E.pdf. Accessed July 2018.
Smith L, Brassard P, Kwong J, et al. Factors associated with initiation and completion of the quadrivalent human papillomavirus vaccine series in an ontario cohort of grade 8 girls. BMC Public Health. 2011;11 https://doi.org/10.1186/1471-2458-11-645.
GlaxoSmithKline. Health Canada Approves Cervarix™, new GSK cervical cancer vaccine. 2010. https://ca.gsk.com/media/594652/final_press_release_cervarix_en.pdf. Accessed 30 July 2018.
Brisson M, Edmunds W. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Mak. 2003;23:76–82.
Cancer Care Ontario. HPV Vaccination. 2012. https://archive.cancercare.on.ca/cms/one.aspx?pageId=8194. Accessed July 2018.
City of Ottawa. Population. http://ottawa.ca/en/long-range-financial-plans/economy-and-demographics/population (2015). Accessed January 2016.
Bednarczyk R, Birkhead G, Morse D, et al. Human papillomavirus vaccine uptake and barriers: association with perceived risk, actualy risk and race/ethnicity among female students at a New York State university, 2010. Vaccine. 2011;29:3138–43.
Ratanasiripong N. What college women know, think, and do about human papillomavirus (HPV) and HPV vaccine [dissertation]. Kansas City: University of Missouri-Kansas City; 2012.
Ajzen I. The theory of planned behavior. Organ Behav Hum. Dec. 1991;50:179–211.
Krawczyk AL, Perez S, Lau E, et al. Human papillomavirus vaccination intentions and uptake in college women. Health Psychol. 2012;31:685–93.
Roberts ME, Gerrard M, Reimer R, Gibbons FX. Mother-daughter communication and human papillomavirus vaccine uptake by college students. Pediatrics. 2010;125:982–9.
Sabiani L, Bremond A, Mortier I, et al. Évaluation de la couverture vaccinale du vaccin anti-hpv : résultats d’une enquête auprès des lycéennes et étudiantes de la région PACA. J Gynecol Obst Bio R. 2012;41:136–44.
INSPQ. HPV Vaccination in Quebec: Knowledge Update and Expert Panel Proposals. https://www.inspq.qc.ca/pdf/publications/1705_VaccVPHQc_MAJConnPropComiteExperts_VA.pdf (2012). Accessed November 2015.
PHAC. Vaccine coverage amongst adult Canadians: Results from the 2012 adult National Immunization Coverage (aNIC) survey. 2014. https://www.canada.ca/en/public-health/services/immunization/vaccine-coverage-amongst-adult-canadians-results-2012-adult-national-immunization-coverage-anic-survey.html. Accessed July 2018.
Government of Canada. Vaccine uptake in Canadian adults: results from the 2014 adult National Immunization Coverage Survey. 2016. https://www.canada.ca/en/public-health/services/publications/healthy-living/vaccine-uptake-canadian-adults-results-2014-adult-national-immunization-coverage-survey.html. Accessed 28 Jan 2017.
Ontario Agency for Health Protection and Promotion (Public Health Ontario). Immunization coverage report for school pupils: 2013–14, 2014–15 and 2015–16 school years. Queen's Printer for Ontario, Toronto. 2017.
Kessels SJ, Marshall HS, Watson M, et al. Factors associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine. 2012;30:3546–56.
Tung IL, Machalek DA, Garland SM. Attitudes, Knowledge and Factors Associated with Human Papillomavirus (HPV) Vaccine Uptake in Adolescent Girls and Young Women in Victoria, Australia. PloS One. 2016;11 https://doi.org/10.1371/journal.pone.0161846.
Coles VA, Patel AS, Allen FL, Keeping ST, Carroll SM. The Association of Human Papillomavirus Vaccination with sexual Behaviours and human papillomavirus knowledge: a systematic review. Int J STD AIDS. 2015;26:777–88.
Giede C, McFadden LL, Komonoski P, et al. The acceptability of HPV vaccination among women attending the University of Saskatchewan Student Health services. J Obstet Gynaecol Can. 2010;32(7):679–86.
Zimet GD, Weiss TW, Rosenthal SL, et al. Reasons for non-vaccination against HPV and future vaccination intentions among 19-26 year-old women. BMC Womens Health. 2010; https://doi.org/10.1186/1472-6874-10-27.
Schurink TM and de Melker HE. HPV vaccination: background information for the Dutch health council. Rijksinstituut voor Volksgezondheid en Milieu RIVM 2017. https://www.rivm.nl/en/Documents_and_publications/Scientific/Reports/2017/mei/HPV_vaccination_Background_information_for_the_Dutch_Health_Council. Accessed 30 July 2018.
Stokley S, Jeyarajah J, Yankey D, et al. Human papillomavirus vaccination coverage among adolescents, 2007–2013, and Postlicensure vaccine safety monitoring, 2006–2014 — United States. Morb Mortal Wkly Rep. 2014;63:620–4.
Thompson EL, Best AL, Vamos CA, Daley EM. “My mom said it wasn't important”: a case for catch-up human papillomavirus vaccination among young adult women in the United States. Prev Med. 2017;1-5:1–4.
Tudrej BV, Rehman MB, Boussageon R. Improving public health information for patients: shared decision making and influenza vaccination. Br J Gen Pract. 2017;67:421–2.
Obulaney PA, Gililand I, Cassells H. Articles increasing cervical Cancer and human papillomavirus prevention knowledge and HPV vaccine uptake through mother/daughter education. J Community Health Nurs. 2016;33:54–67.
Bynum SA, Wright MS, Brandt HM, et al. Knowledge, beliefs, and attitudes related to human papillomavirus infection and vaccination, pap tests, and cervical intraepithelial neoplasia among adolescent girls and young women. J S C Med Assoc. 2009;105:267–72.
Jantzi-Bauman M. Expansion of the school-based human papillomavirus (HPV) vaccine program.Public Health Wellington-Dufferin-Guelph 2017. https://wdgpublichealth.ca/sites/default/files/file-attachments/basic-page/bh.01.apr0517.r10_-_expansion_of_the_school-based_hpv_vaccine_program_access.pdf. Accessed 9 Feb 2018.
Fernandez ME, Debor M, Candreia MJ, et al. Evaluation of ENCOREplus. A community-based breast and cervical cancer screening program. Am J Prev Med. 1999;16:35–49.